Medication
|
Trade name
|
Primary Indication
|
Company
|
2015
|
2014
|
2013
|
2012
|
2011
|
2010
|
2009
|
2008[1][2][3][4][5][6]
|
2007[7][8][9][10][11][12]
|
2006[13][14][15][16][17][18]
|
2005[19][20][21][22][23]
|
2004[24][25][26][27]
|
2003[28][29][30][31]
|
2002[32][33][34][35]
|
2001[36]
|
2000[37][38]
|
atorvastatin
|
Lipitor
|
Reduction of LDL cholesterol
|
Pfizer
|
|
|
|
|
|
|
|
$12,401
|
$12,675
|
$12,886
|
$12,187
|
$10,862
|
$9,231
|
$7,972
|
$6,448
|
$5,028
|
sunitinib malate
|
Sutent
|
Advanced and/or metastatic renal cell carcinoma (mRCC) & refractory gastrointestinal stromal tumors (GIST)
|
Pfizer
|
|
|
|
|
|
|
|
$847
|
$581
|
$219
|
|
|
|
|
|
|
irinotecan
|
Camptosar
|
Metastatic colorectal cancer
|
Pfizer
|
|
|
|
|
|
|
|
$563
|
$969
|
$903
|
$910
|
$554
|
$299
|
|
|
|
bimatoprost
|
Lumigan
|
Open-angle glaucoma or ocular hypertension
|
Allergan
|
|
|
|
|
|
|
|
$426.2
|
$391.7
|
$327.5
|
$267.6
|
$232.9
|
$181.3
|
$123
|
$35.4
|
|
exemestane
|
Aromasin
|
Breast cancer
|
Pfizer
|
|
|
|
|
|
|
|
$465
|
$401
|
$320
|
$247
|
$143
|
$58
|
|
|
|
epirubicin
|
Ellence
|
Breast cancer
|
Pfizer
|
|
|
|
|
|
|
|
|
|
$312
|
$367
|
$344
|
$216
|
|
|
|
trastuzumab
|
Herceptin
|
HER2-positive metastatic breast cancer
|
Genentech
|
|
|
|
|
|
|
|
$1,382
|
$1,287
|
$1,234
|
$747.2
|
$483.2
|
$424.8
|
$385.2
|
$346.7
|
$276
|
gemcitabine
|
Gemzar
|
Ovarian cancer, non-small cell lung cancer (NSCLC), metastatic breast cancer (MBC), and pancreatic cancer
|
Eli Lilly & Co.
|
|
|
|
|
|
|
|
$1,719.8
|
$1,592.4
|
$1,408.1
|
$1,334.5
|
$1,214.4
|
$1,021.7
|
$875
|
$723
|
$559.3
|
bevacizumab
|
Avastin
|
Metastatic colorectal cancer, non-small cell lung cancer (NSCLC), renal cell carcinoma, HER2-negative breast cancer
|
Genentech
|
|
|
|
|
|
|
|
$2,686
|
$2,296
|
$1,746
|
$1,132
|
$554.6
|
|
|
|
|
erlotinib
|
Tarceva
|
Advanced (metastatic) non-small cell lung cancer (NSCLC)
|
Genentech
|
|
|
|
|
|
|
|
$457
|
$417
|
$402
|
$274.9
|
$13.3
|
|
|
|
|
brimonidine
|
Alphagan
|
Open-angle glaucoma or ocular hypertension
|
Allergan
|
|
|
|
|
|
|
|
|
|
|
|
|
$286.8
|
$248.5
|
$250.9
|
|
rituximab
|
Rituxan
|
Non-Hodgkin's lymphoma and rheumatoid arthritis
|
Genentech
|
|
|
|
|
|
|
|
$2,587
|
$2,285
|
$2,071
|
$1,831.4
|
$1,574
|
$1,360.2
|
$1,162.9
|
$818.6
|
|
ranibizumab
|
Lucentis
|
Age-related macular degeneration (AMD)
|
Genentech
|
|
|
|
|
|
|
|
$875
|
$815
|
$380
|
|
|
|
|
|
|
omalizumab
|
Xolair
|
Asthma
|
Genentech
|
|
|
|
|
|
|
|
$517
|
$472
|
$425
|
$320.6
|
$187.6
|
$25.1
|
|
|
|
somatropin
|
Nutropin
|
Growth hormone deficiency, chronic kidney disease
|
Genentech
|
|
|
|
|
|
|
|
$358
|
$371
|
$378
|
$370.5
|
$348.8
|
$319.5
|
|
|
|
dornase alfa
|
Pulmozyme
|
Cystic fibrosis (CF)
|
Genentech
|
|
|
|
|
|
|
|
$257
|
$223
|
$199
|
$186.5
|
$157.1
|
$143.7
|
$138.1
|
$123
|
|
efalizumab
|
Raptiva
|
Plaque psoriasis
|
Genentech
|
|
|
|
|
|
|
|
$108
|
$107
|
$90
|
$79.2
|
$52.4
|
$1.4
|
|
|
|
montelukast
|
Singulair
|
Asthma
|
Merck
|
|
|
|
|
|
|
|
$4,336.9
|
$4,266.3
|
$3,579
|
$2,975.6
|
$2,622
|
|
|
|
|
alendronate sodium
|
Fosamax
|
Postmenopausal osteoporosis
|
Merck
|
|
|
|
|
|
|
|
$1,552.7
|
$3,049
|
$3,134.4
|
$3,191.2
|
$3,159.7
|
|
|
|
|
sitagliptin
|
Januvia
|
Type 2 diabetes
|
Merck
|
|
|
|
|
|
|
|
$1,397.1
|
$667.5
|
$42.9
|
|
|
|
|
|
|
simvastatin
|
Zocor
|
Reduction of LDL cholesterol
|
Merck
|
|
|
|
|
|
|
|
$660.1
|
$876.5
|
$2,802.7
|
$4,381.7
|
$5,196.5
|
|
|
|
|
rizatriptan benzoate
|
Maxalt
|
Migraine pain
|
Merck
|
|
|
|
|
|
|
|
$529.2
|
$467.3
|
$406.4
|
$348.4
|
$309.9
|
|
|
|
|
finasteride
|
Propecia
|
Hair loss
|
Merck
|
|
|
|
|
|
|
|
$429.1
|
$405.4
|
$351.8
|
$291.9
|
$270.2
|
|
|
|
|
etoricoxib
|
Arcoxia
|
Osteoarthritis and rheumatoid arthritis
|
Merck
|
|
|
|
|
|
|
|
$377.3
|
$329.1
|
$265.4
|
$218.2
|
|
|
|
|
|
sitagliptin/metformin HCl
|
Janumet
|
Type 2 diabetes
|
Merck
|
|
|
|
|
|
|
|
$351.1
|
$86.4
|
|
|
|
|
|
|
|
finasteride
|
Proscar
|
Benign prostatic hyperplasia (enlarged prostate)
|
Merck
|
|
|
|
|
|
|
|
$323.5
|
$411
|
$618.5
|
$741.4
|
$733.1
|
|
|
|
|
aprepitant
|
Emend
|
Nausea and vomiting prevention caused by chemotherapy
|
Merck
|
|
|
|
|
|
|
|
$263.8
|
$204.2
|
$130.8
|
$87
|
|
|
|
|
|
olanzapine
|
Zyprexa
|
Schizophrenia
|
Eli Lilly & Co.
|
|
|
|
|
|
|
|
$4,696.1
|
$4,761
|
$4,363.6
|
$4,202.3
|
$4,419.8
|
$4,276.9
|
$3,689
|
$3,087
|
$2,349.5
|
duloxetine HCl
|
Cymbalta
|
Depression and generalized anxiety disorder
|
Eli Lilly & Co.
|
|
|
|
|
|
|
|
$2,697.1
|
$2,102.9
|
$1,316.4
|
$679.7
|
$93.9
|
|
|
|
|
insulin lispro
|
Humalog
|
Type 1 diabetes in adults
|
Eli Lilly & Co.
|
|
|
|
|
|
|
|
$1,735.8
|
$1,474.6
|
$1,299.5
|
$1,197.7
|
$1,101.6
|
$1,021.3
|
$834
|
$628
|
$350.2
|
pemetrexed
|
Alimta
|
Locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC)
|
Eli Lilly & Co.
|
|
|
|
|
|
|
|
$1,154.7
|
$854
|
$611.8
|
$463.2
|
$142.6
|
|
|
|
|
raloxifene HCl
|
Evista
|
Osteoporosis
|
Eli Lilly & Co.
|
|
|
|
|
|
|
|
$1,075.6
|
$1,090.7
|
$1,045.3
|
$1,036.1
|
$1,012.7
|
$922.1
|
$822
|
$665
|
$521.5
|
insulin isophane
|
Humulin
|
Diabetes
|
Eli Lilly & Co.
|
|
|
|
|
|
|
|
$1,063.2
|
$985.2
|
$925.3
|
$1,004.7
|
$997.7
|
$1,060.4
|
$1,004
|
$1,061
|
$1,114.5
|
teriparatide
|
Forteo
|
Osteoporosis
|
Eli Lilly & Co.
|
|
|
|
|
|
|
|
$778.7
|
$709.3
|
$863.3
|
$389.3
|
$238.6
|
$65.3
|
|
|
|
atomoxetine HCl
|
Strattera
|
Attention-deficit/hyperactivity disorder (ADHD)
|
Eli Lilly & Co.
|
|
|
|
|
|
|
|
$579.5
|
$569.4
|
$579
|
$552.1
|
$666.7
|
$370.3
|
|
|
|
timolol
|
Istalol
|
Open-angle glaucoma
|
Ista Pharmaceutical
|
|
|
|
|
|
|
|
$14.6
|
$11.3
|
$8.3
|
$2.6
|
|
|
|
|
|
bromfenac
|
Xibrom
|
Ocular inflammation
|
Ista Pharmaceutical
|
|
|
|
|
|
|
|
$63
|
$42.1
|
$20.2
|
$5.3
|
|
|
|
|
|
hyaluronidase
|
Vitrase
|
Spreading agent
|
Ista Pharmaceutica
|
|
|
|
|
|
|
|
$5.2
|
$5.2
|
$4.2
|
$2.5
|
|
|
|
|
|
rivaroxaban
|
Xarelto
|
Deep vein thrombosis
|
Johnson & Johnson[39]
|
$1,868
|
$1,522
|
$864
|
$239
|
$25
|
|
|
|
|
|
|
|
|
|
|
|